Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Deucravacitinib helped a man regrow hair and improve psoriasis.

Dermatologists need more training on isotretinoin's eye side effects.

Deucravacitinib helped a man regrow hair significantly.

High potency topical steroids are the most effective treatment for pediatric alopecia areata.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.

Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

Bexarotene gel shows promise as a new treatment for alopecia areata.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.

A 6-year-old girl with alopecia universalis regrew most of her hair after treatment with simvastatin/ezetimibe, minoxidil, and prednisolone.

CS12192 effectively treats alopecia areata with better safety than current options.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Baricitinib shows promise for treating alopecia areata with mild side effects.